Latest / CME Outfitters Medical Education / From Biomarkers to Bedside: Translating IIM Classification into Targeted Treatment Strategies
Transcript
- 0:00SPEAKER_00: Hello.
- 0:01SPEAKER_00: On behalf of the CME Outfitters, I would like to welcome everyone and thank you for joining us today.
- 0:08SPEAKER_00: And on this engage the experts activity from biomarkers to bedside, translating IAM classification into targeted treatment strategies.
- 0:20SPEAKER_00: This activity is supported through an independent educational grant from RGNX.
- 0:25SPEAKER_00: And over the next hour, we will work through three clinical cases that reflect common challenges in idiopathic inflammatory myopathy.
- 0:34SPEAKER_00: We will consider how clinical phenotype, biomarker findings, imaging, pathology, and patient-specific factors can help us determine what type of IAM we are dealing with, what that classification should change about the rest of the patient's care, and how it should inform treatment decisions.
- 0:55SPEAKER_00: This activity may include discussion of products or devices that are not currently labeled for use by the US Food and Drug FDA.
- 1:08SPEAKER_00: As faculty, we have been informed of our responsibility to disclose any off-label or investigational use when it is discussed.
- 1:19SPEAKER_00: So portions of the presentation were developed with generative AI assistance.
- 1:25SPEAKER_00: All AI generated content was treated as draft material, verified against primary sources, and reviewed for scientific accuracy, fair balance, and compliance.
- 1:37SPEAKER_00: AI was not the sole reviewer for this presentation.
- 1:42SPEAKER_00: And this is the staff that you, the faculty on this.
- 1:47SPEAKER_00: And I am Mamata Pasnour.
- 1:49SPEAKER_00: I'm a neuromuscular physician.
- 1:51SPEAKER_00: I'm a professor at University of Kansas Medical Center.
- 1:55SPEAKER_00: And today I'm joined by Dr.
- 1:58SPEAKER_00: Muzaffar and Dr.
- 1:59SPEAKER_00: Nidaf, two excellent neuromuscular physicians who I'll allow them to introduce themselves.
- 2:06SPEAKER_00: Dr.
- 2:06SPEAKER_00: Muzaffar, you want to introduce yourself?
- 2:08SPEAKER_03: Sure, thank you.
- 2:10SPEAKER_03: This is Tesi Muzaffar.
- 2:11SPEAKER_03: I'm a professor of neurology and pathology at the University of California, Irvine, and part of the division of neuromuscular medicine in the Department of Neurology.
- 2:22SPEAKER_02: Hi, and I'm Elina Daff.
- 2:24SPEAKER_02: I'm an associate professor of neurology at Mayo Clinic in Rochester, Minnesota.
- 2:29SPEAKER_02: I'm also a part of the neuromuscular division and a muscle pathologist.
- 2:35SPEAKER_00: Thank you.
- 2:36SPEAKER_00: And these are the disclosures as shown here.
- 2:41SPEAKER_00: All identified conflicts of interest have been mitigated.
- 2:47SPEAKER_00: And going on to the first objective, here is a the first objective is apply biomarker-informed diagnostic strategies to differentiate major IAM subtypes and distinguish inflammatory disease from key mimics.
- 3:04SPEAKER_00: So let's go on to introduce our first patient, Michael.
- 3:11SPEAKER_00: He's a 52-year-old male presenting with four months of progressive difficulty rising from the chair and lifting overhead his arms.
- 3:21SPEAKER_00: And there's no rash, no dysphagia, no bulbar symptoms, no dysnea, no new medications or family history.
- 3:28SPEAKER_00: And the patient was referred with the working diagnosis of polymyositis.
- 3:33SPEAKER_00: And on examination, there's symmetric proximal weakness in hip flexus and shoulder abductus and distal strength as normal.
- 3:41SPEAKER_00: CK was elevated as you can see here, and the myositis-specific antibody panel was negative.
- 3:49SPEAKER_00: The 52-year-old male with four months of progressive symmetric proximal weakness with elevated CK, negative myositis serology.
- 3:57SPEAKER_00: And now, which interpretation should guide the next diagnostic step.
- 4:19SPEAKER_00: Hold that answer for some time as we go through and we'll come back to the same decision after we work through the diagnostic framework.
- 4:31SPEAKER_00: And uh, Dr.
- 4:32SPEAKER_00: Nidav, uh, can you please take us through the classification of IIM?
- 4:38SPEAKER_02: Of course.
- 4:38SPEAKER_02: So there are different diseases that fall under IIM.
- 4:42SPEAKER_02: I would start with the inclusion body myositis, as it's a standalone disease that's characterized by slowly progressive weakness that happens in an aging population.
- 4:52SPEAKER_02: And some might argue whether you would classify it under IIM or not, versus the other form that are characterized by rapidly progressive weakness.
- 5:03SPEAKER_02: One is immune-mediated necrotizing myopathy that usually presents with progressive muscle weakness.
- 5:10SPEAKER_02: It's usually a pure muscle disease.
- 5:12SPEAKER_02: Then the other categories represent the systemic inflammatory myopathy, which include dermatomyositis with skin manifestation, anticentatase syndrome, or overlap myositis when patients have features of meozitis and another connective tissue disease.
- 5:29SPEAKER_02: Then the last entity would be polymyozitis.
- 5:32SPEAKER_02: Because people could sometimes just diagnose patients with polymyositis where there is no clear diagnosis, it has become a sign of misdiagnosis.
- 5:44SPEAKER_02: While polymyositis from a pathological standpoint indicate endomesial inflammation where the inflammatory cells are invading the muscle fibers, so people would argue that are for the vast majority of patients, these would be patient with inclusion body meositis.
- 6:03SPEAKER_02: Therefore, the term is not commonly used.
- 6:06SPEAKER_02: Now, there are a lot of features that distinguish these entities apart.
- 6:12SPEAKER_02: As we said, inclusion body meositis and IMNM are pure muscular diseases.
- 6:17SPEAKER_02: One is rapidly progressive, one is slowly progressive.
- 6:20SPEAKER_02: So you don't see much systemic manifestations with them.
- 6:24SPEAKER_02: Unlike dermatomyozitis, that can have a distinctive skin rash, anti-centitase syndrome, when you can have mechanic hands, arthritis, lung involvement, and overlap meiozitis that can have overlapping features.
- 6:40SPEAKER_02: Each entity has also its own antibodies.
- 6:43SPEAKER_02: Most of them are called myozitis-specific antibodies that are only seen in meozitus, while other meositis are called associated antibodies that just help us raise suspicion of an underlying immune disorder.
- 6:59SPEAKER_02: I think one thing to mention there is that there's patients that fall on the spectrum between these entities and that can have features that overlap between one category or the other.
- 7:15SPEAKER_03: Thank you, Dr.
- 7:16SPEAKER_03: Nadalf.
- 7:17SPEAKER_03: So I'd like to go over the different aspects of the disease that you want to consider for making a diagnosis.
- 7:25SPEAKER_03: Obviously, the tempo is important.
- 7:27SPEAKER_03: Most of these myocites present subacutely, whereas IBM tend generally tends to be chronic and the disease progresses over years rather than months or weeks.
- 7:40SPEAKER_03: Acute weakness is unusual in myocitis and it's more typical for infectious myocitis or toxic myocitis.
- 7:47SPEAKER_03: Distribution is also important.
- 7:48SPEAKER_03: Like all other muscle diseases, myocytes tend to be symmetric.
- 7:54SPEAKER_03: The exception to that rule is IBM, where there is asymmetry and selective involvement of forearm finger flexors and knee extensor weakness as well.
- 8:06SPEAKER_03: The lower extremity is much more affected in IMNM and anti-synthesis, but there's nothing specific about hamstring weakness.
- 8:15SPEAKER_03: Hamstring weakness can also be seen in inherited myopathies.
- 8:19SPEAKER_03: So unfortunately, that does not help you.
- 8:21SPEAKER_03: So other than possibly involvement of finger flexors and quadriceps, there are nothing specific in terms of distribution of weakness.
- 8:29SPEAKER_03: And finally, I want to say a word about CK.
- 8:32SPEAKER_03: You can have normal CK in myocitis, especially dermatomyocytis.
- 8:36SPEAKER_03: Dermatomyocitis is notorious for having normal CK despite tremendous disease activity seen in all types of dermato, um, um, but especially anti-MDA5 and dermato, which can be amyopathic as well.
- 8:54SPEAKER_03: Um, IMNM typically has CK values of greater than 1000, often greater than 5000.
- 9:02SPEAKER_03: But in all of these diseases, you can have burnt out disease or relatively stable disease, and their CKs can be normal.
- 9:13SPEAKER_03: Now, um, when you look at um pattern of uh involvement of other ancillary testing, there's nothing specific about EMG and MRI.
- 9:23SPEAKER_03: So you can never make a definitive diagnosis of myositis based on EMG or muscle MRI and um and that.
- 9:31SPEAKER_03: So I'll I'll start with EMG.
- 9:33SPEAKER_03: All EMG will achieve is that you can show that the nerve conductions are normal when it comes to conduction velocity and latencies.
- 9:42SPEAKER_03: You may have reduced amplitude on the of the motor conduct motor amplitudes, and you will see fibrillation potentials that is suggestive of active muscle involvement.
- 9:55SPEAKER_03: Fibrillation potentials are not specific for neurogenic disease, so it's used as an ancillary marker of ongoing disease activity, and EMT helps to guide which muscle to be picked for muscle biopsy.
- 10:09SPEAKER_03: Um, the MRI can does not have to be extensive.
- 10:13SPEAKER_03: We do MRIs without contrast and we choose a T1 weighted image and a stir-weighted uh weighted image to look for fat infiltration and edema.
- 10:23SPEAKER_03: Edema is relatively early in the disease and ultimately will lead to fat replacement.
- 10:29SPEAKER_03: Um, edema is not specific.
- 10:31SPEAKER_03: Neurogenic disease will also give you edema.
- 10:34SPEAKER_03: So it's a source of great irritation for us when radiologists call the MRI as myositis based on star imaging, which is not true.
- 10:45SPEAKER_00: So Michael is zero-negative, and we still have diagnostic uncertainty and clinical assessment and localization workup.
- 10:52unknown: Dr.
- 10:53SPEAKER_00: Muzafar, this is where you specifically wanted pathology to have more visibility.
- 10:57SPEAKER_00: What can the biopsy tell us and which findings truly you think would help us distinguish one IM from the other subtype?
- 11:06SPEAKER_03: Sure, and and with the disclaimer that both Dr.
- 11:08SPEAKER_03: Nataf and I are uh enormous fans of muscle pathology, and we still think that muscle pathology has a role, even in cases that have antibody positivity in that.
- 11:19SPEAKER_03: So there are specific patterns to myopathology.
- 11:22SPEAKER_03: In classical DM, you have perifyscicular atrophy and microangiopathy, you have capillary deposits of complement pathway, especially the terminal cascade, you have perivascular or perimycel lymphocytic infiltration, and a very unique pattern of MHC class 1 upregulation in the perifasicular region with the peripheral to central gradient.
- 11:44SPEAKER_03: IMNM is a more diffuse process.
- 11:47SPEAKER_03: You have a large number of necrotic and regenerating fibers without any clear lymphocytic inflammation.
- 11:55SPEAKER_03: So it's it that's why the reason we don't call it myocytis is because it's um it's a myopathy and it's a necrotizing myopathy.
- 12:04SPEAKER_03: There is marked elevation of CK and the MHC upregulation, it's primarily in fibers that are necrotic and um or undergoing regeneration.
- 12:14SPEAKER_03: Uh anti-synthetis syndrome almost looks like dermatomyocitis.
- 12:19SPEAKER_03: There are fundamental differences, um, unlike dermatovere, there is perifiscicular atrophy in antisynthetis, there is perifysicular necrosis and regeneration, marked um inflammation in the perimycal connective tissue and fragmentation of the connective tissue and very marked alkaline phosphatase activity.
- 12:39SPEAKER_03: We now use um a specific interferon alpha protein called uh myxoma resistance antigen type A or MXA, um, and it has high specificity and very high specific uh very high sensitivity and very high specificity for diagnosis of dermatomyocitis.
- 13:00SPEAKER_03: It's expressed in the periphysicular region, um, and it helps us distinguish dermatocases from anti-synthesis.
- 13:08SPEAKER_03: So, biopsy helps.
- 13:11SPEAKER_03: There are also unique biopsy features of the antibody subtypes in dermatomyocitis, and I still feel the antibody uh biopsies are important.
- 13:21SPEAKER_03: You are more likely to biopsy if the antibodies are either negative or inconclusive.
- 13:29SPEAKER_03: Um, an abnormal MRI with edema should be biopsy because you can still have neurogenic changes, and sometimes we see patients with ALS and other neurogenic disease on biopsy that were thought to be myositis.
- 13:44SPEAKER_03: Um, the tendency to biopsy goes down when you have antibodies and have a classic dermatol rash, although, as I said, I still believe in biopsies, and the clinical exam should select the biopsy.
- 13:57SPEAKER_03: You want to pick a muscle that is has a moderate amount of weakness, not too weak, not too strong, because that will give you the best results.
- 14:08SPEAKER_00: Thank you, Dr.
- 14:08SPEAKER_00: Muzafar.
- 14:10SPEAKER_00: So uh I do see some questions coming in, uh, which uh keep them coming in.
- 14:14SPEAKER_00: However, the some of our future slides will um will give uh answers to this.
- 14:21SPEAKER_00: So keep going, uh we'll continue this and then we'll come back to the questions.
- 14:25SPEAKER_00: Michael's panel came back negative.
- 14:28SPEAKER_00: Um, and Dr.
- 14:29SPEAKER_00: Nadav, does that change your diagnosis or uh or your next test?
- 14:36SPEAKER_02: It does not.
- 14:37SPEAKER_02: Uh the antibodies are helpful when they are present, uh, there, but their absence does not mean the patient does not have meozitis.
- 14:47SPEAKER_02: And the antibodies, when they're present, have to be also interpreted in light of the clinical context, as they can also be falsely positive.
- 14:56SPEAKER_02: So a good proportion of meozitis patients, probably around 30%, are seronegative, and hence the possibility of meozitis remains even if the antibody is negative.
- 15:10SPEAKER_02: There are no great diagnostic criteria yet for meositis, as all the available criteria have some limitations, but also in clinical practice, we don't heavily rely on diagnostic criteria, but rather on clinical interpretation, assessing the clinical finding, and try to use multimodality testing to try to resolve the diagnosis, especially in the seronegative cases.
- 15:39SPEAKER_02: But there are some red flags to consider that might point to a different diagnosis.
- 15:46SPEAKER_02: For instance, uh, in patient with very young onset, or the tempo of the disease does not fit like a very lingering course of the disease, or if there is any treatment refractoriness, all of these should raise concerns whether the diagnosis is accurate.
- 16:03SPEAKER_02: And even when patients have a positive antibody, and sometimes they have a false positive antibody.
- 16:10SPEAKER_02: If there are some red flags, that's an invitation for further investigation.
- 16:14SPEAKER_02: And obviously, if a muscle biopsy is available, that would be an indication also to consider a muscle biopsy and try to establish diagnosis with more certainty.
- 16:26SPEAKER_02: I think one main issue is also all the issue that we've had with the misdiagnosis with polymyositis.
- 16:33SPEAKER_02: I think it's dangerous to approach patients thinking that myositis is the only possibility and we have to fit them into a category.
- 16:42SPEAKER_02: And everyone who didn't fit in a category or who did not have an antibody, we just put them in polymyositis.
- 16:50SPEAKER_02: Well, actually, myositis is not the only disease that can present similarly.
- 16:54SPEAKER_02: We have to keep the differential diagnosis open to keep toxic myopathies, metabolic myopathies, um, some hereditary myopathies can also have a bit of a more rapid progression and keep the differential diagnosis open and not have to force the patient into a myositis subcategory.
- 17:18SPEAKER_00: Thank you, Latinadaf.
- 17:20SPEAKER_00: And uh, so these five uh referral triggers, uh, five reasons to refer uh may not be in a sequence, but any one of them can be sufficient when the diagnosis of or clinical course is not behaving as you would expect.
- 17:36SPEAKER_00: So, what do you wish community clinicians and all uh had already done before the patient reaches you?
- 17:44unknown: Dr.
- 17:44SPEAKER_00: Nadal, if you want to take that first?
- 17:47SPEAKER_02: Yes, of course.
- 17:48SPEAKER_02: Um, there is nothing specific that I wish they had done.
- 17:52SPEAKER_02: Probably one challenge I see in the practice that patients can come with very limited information.
- 17:58SPEAKER_02: So I think just sending all those records, the details of the treatment, the dates, and all of those will make their assessment goes much smoother.
- 18:07SPEAKER_02: Anything from testing perspective could then be done at the referral center.
- 18:12SPEAKER_02: So I don't think necessarily the local providers will have to do a little bit more testing before sending the patient.
- 18:19SPEAKER_02: The only thing I sometimes I run into is I feel like if there is access and there is an option to send the patient to a referral center or neuromuscular specialist, if the patient is having any struggle with the treatment, that should be a direct trigger to refer.
- 18:36SPEAKER_02: Because sometimes we see patients who have failed multiple lines of therapies before referral while the diagnosis was incorrect.
- 18:44SPEAKER_02: So that would be the only thing if possible, referring sooner rather than later would be preferable.
- 18:52SPEAKER_03: And I want to emphasize what Dr.
- 18:53SPEAKER_03: Nadaf has already covered.
- 18:55SPEAKER_03: They can be false negatives for the myositis antibodies.
- 18:59SPEAKER_03: Um just because you have a positive antibodies that does not in itself establish the diagnosis, you also always have to be open.
- 19:08SPEAKER_03: And generally, if the patient requires muscle biopsy, it's better to refer to a specialized center that has experience experience with interpretation of myopathology and myositis.
- 19:21SPEAKER_00: Thank you, Dr.
- 19:22SPEAKER_00: Nadap and Dr.
- 19:23SPEAKER_00: Muzaffar.
- 19:23SPEAKER_00: And uh going back to our question, our 52-year-old male who has four months of progressive symmetric proximal weakness with an elevated CK and uh negative myositis serology, what would I mean now within which interpretation should guide your next diagnostic step?
- 19:58SPEAKER_00: So one of the one of the questions, so you can see the results here, use emg and muscle MRI to characterize.
- 20:07SPEAKER_00: I think that's uh that is um about 50% of the of the audience looks like has uh selected that.
- 20:16SPEAKER_00: And uh based on all the discussions we had, that's the correct answer.
- 20:21SPEAKER_00: And uh just wanna let me.
- 20:23SPEAKER_00: I'm just uh looking at the questions that came in, and one of the questions was how would you interpret positive sharp waves but not no fibrillations on EMG?
- 20:32SPEAKER_00: Is it is this still considered an irritable muscle and possibly indicative of inflammation?
- 20:38SPEAKER_00: Uh, Dr.
- 20:38SPEAKER_00: Humuzafar, do you want to take that?
- 20:44SPEAKER_03: Sure.
- 20:44SPEAKER_03: To me, positive sharp waves is the same as fibrillations.
- 20:48SPEAKER_03: They're both uh evidence for uh irritability, and irritability in a setting of myositis means possible inflammation.
- 20:56SPEAKER_03: So I think either of them would be good enough.
- 20:59SPEAKER_00: Sounds good.
- 21:00SPEAKER_00: We'll go on with the presentation and we'll come back to the questions again in a few minutes.
- 21:06SPEAKER_00: And going on to our next learning objective: utilize uh IM subtype for to inform comorbidity assessment, multidisciplinary management, and quality of life improvement.
- 21:19SPEAKER_00: So, for this, we'll go with our next case, Diana.
- 21:23SPEAKER_00: She's a 68-year-old female who presents with anti-JO1 uh positive antisynthetic syndrome, diagnosed three years ago.
- 21:31SPEAKER_00: Uh she has mild proximal weakness, and she's on methotrexate, stable on it for some time, mechanics, hands, uh, she has Rhinard's phenomenon, three months of progressive exertional dysnea, and dry cough.
- 21:44SPEAKER_00: She was referred uh back to rheumatology as myositis flare up, and her muscle examination is essentially unchanged and CK mildly elevated.
- 21:53SPEAKER_00: Uh, the FVC was um 68% predicted, the LCO was 52% predicted.
- 22:00SPEAKER_00: Which comorbidity should be prioritized for immediate evaluation and what is the next step in management?
- 22:06SPEAKER_00: So these are common questions that we all face.
- 22:10SPEAKER_00: Let's talk about.
- 22:12SPEAKER_03: Sure.
- 22:13SPEAKER_03: So the biggest concern in anti-setis syndrome, whether it's JO1 antibodies or any of the other anti-synthetis antibodies, is the development of interstitial lung disease.
- 22:25SPEAKER_03: Epidemiology studies suggest that the incidence of ILD may be as high as 65 to 70%.
- 22:33SPEAKER_03: So that's a complication we always are looking at or in or interested in assessing.
- 22:39SPEAKER_03: And if there is evidence, especially in the in the face of reduced diffusion capacity or reduced forcewalk capacity, the patient's pulmonary evaluation needs to be prioritized and requires a high-resolution CT scan and consultation with a pulmonary expert.
- 22:59SPEAKER_00: Thank you, Dr.
- 23:00SPEAKER_00: Mazafar.
- 23:01SPEAKER_00: So here's a question again, and the answers a 68-year-old female with the JO1 positive antibody anti-synthetis syndrome has progressive dysnea, dry cough, unchanged muscle findings, FEC was 68% predicted, DLCO 52% predicted.
- 23:19SPEAKER_00: Which next step should be prioritized?
- 23:38SPEAKER_00: Okay, hold that answer for some time.
- 23:41SPEAKER_00: We'll come back to that question again.
- 23:43SPEAKER_00: We have identified uh Dynasty anti-synthetic syndrome.
- 23:47SPEAKER_00: Now the question becomes what's the classification, what class what that classification should change about the rest of a care?
- 23:54SPEAKER_00: Uh Dr.
- 23:55SPEAKER_00: Mazafar, can you use this table to show us how subtype determines which complications we actively screen for?
- 24:04SPEAKER_03: And thank you, uh Mampa.
- 24:06SPEAKER_03: The um the presence of antibodies is not only diagnostic but really helps us with prognosis.
- 24:12SPEAKER_03: So in dermatomyocitis, certain antibodies increase the risk of interstitial lung disease, especially MDA5, whereas antibodies such as TIF1 gamma and NXP2 increase the risk of malignancy.
- 24:27SPEAKER_03: Um XP2 also increases the risk of calcinosis.
- 24:32SPEAKER_03: In antisynthesis syndrome, uh again, all antibodies are associated with in risk of interstitial lung disease, especially the PL7, PL12 are more centric to the to the lungs.
- 24:48SPEAKER_03: Malignancy is a low risk factor in antisynthesis syndrome.
- 24:51SPEAKER_03: IMNM, interstitial lung disease is less common, but perhaps more common in SRP antibody-related IMNM versus HMGCR and IMNM, and the risk of malignancy is intermediate and maybe a little bit more in HMGCR and also in zero-negative uh IMNM, which is not listed here.
- 25:15SPEAKER_03: Um, IBM usually does not have a risk of ILD and screening is not a major concern.
- 25:22SPEAKER_03: I mean screening for malignancy is not a major concern in IBM.
- 25:30SPEAKER_03: So um when when you have a suspicion um of interstitial lung disease um uh in uh a patient with myositis, the tests that we routinely recommend are the pulmonary function test, and this is the full battery with spirometry, lung volumes, and diffusion capacities, high resolution um chest CT, um, and uh ideally you want to do both PFTs in high resolution CT, one or the other will not suffice.
- 26:02SPEAKER_03: And then you want to estimate your risks in the thing.
- 26:05SPEAKER_03: As I mentioned, some antibodies have very high risk, such as MTM MDF5 and anti synthetis, whereas other antibodies, especially HMGCR and IM and IBM, does not have that risk.
- 26:19SPEAKER_03: Um, chest x-rays alone are not good enough, and we routinely do not use uh six-minute walk distance, ambulatory desaturation or bronchoscopy, and we almost never recommend a surgical lung biopsy unless there is a concern for malignancy there.
- 26:37SPEAKER_03: But in special cases, especially if you want to look at exercise tolerance, um, looking at six-minute walk distance or bronchoscopy, etc., may be suitable.
- 26:47SPEAKER_03: Generally, for high-risk cases, we want to do PFTs more frequent, low-risk cases once a year may be good enough, but in the first year, you want to do PFTs NHRCT much more frequent, and then once you have ruled out malignancy and and one year has passed, you can make it less frequent.
- 27:09SPEAKER_00: Thank you, Dr.
- 27:10SPEAKER_00: Muzaffar.
- 27:11SPEAKER_00: In this um, in this case, dianas uh pulmonary function tests are abnormal, but the pattern matters.
- 27:19SPEAKER_00: Not every reduction in FPC, as you uh mentioned in uh a bit earlier, points to interstitial lung disease.
- 27:26SPEAKER_00: Dr.
- 27:26SPEAKER_00: Muzaffar, walk us through how you use the FVC and the DLCO together to decide what process you need to investigate next.
- 27:35SPEAKER_00: I think you uh touched on a little earlier, but just wanted to see if you can.
- 27:40SPEAKER_03: Yeah, and and again, I'd I'd love to hear from Dr.
- 27:43SPEAKER_03: Nadaf as well on this.
- 27:44SPEAKER_03: But generally, low FVC is suggestive of a muscle weakness or restrictive lung disease, whereas DLCO2 is an index of um diffusion capacity of the lung parenchyma.
- 27:59SPEAKER_03: But they're not unique to um a myositis.
- 28:04SPEAKER_03: Your emphysema or pulmonary hypertension can lead to reduced uh DLCO2, and there are other diseases that can reduce your FVC, or FVC sometimes may be normal in muscle disease.
- 28:18SPEAKER_03: We see that particularly in Pompeii disease, where your FVC can be normal but your diaphragmatic pressures can be low.
- 28:25SPEAKER_03: So you always have to look at the overall picture and see if there is any suggestion of perencamel disease as well as muscle disease.
- 28:36SPEAKER_03: Dr.
- 28:36SPEAKER_03: Nadav, would you agree with that?
- 28:38SPEAKER_02: Yeah, I agree.
- 28:39SPEAKER_02: I like to complement it also with overnight oximetry.
- 28:43SPEAKER_02: Um, that gives us an idea in neuromuscular respiratory weakness, you can start seeing some desaturation during REM sleep.
- 28:50SPEAKER_02: Some centers do FVC supine versus standing, but not always.
- 28:55SPEAKER_02: And it's important, I would just add one thing the FVC is not low due to an obstructive component.
- 29:01SPEAKER_02: So in those patients, the FEV1 to FVC ratio would be normal.
- 29:06SPEAKER_02: And that would make you think of neuromuscular respiratory weakness rather than asthma or other obstructive components.
- 29:13SPEAKER_03: And I want to complement that by saying that the inspiratory pressures and the expiratory pressures are a very important, important test in pulmonary function.
- 29:22SPEAKER_03: They directly measure the diaphragmatic strength and the external intercostal strength, which may be affected and may be affected out of proportion to the FEC.
- 29:30SPEAKER_03: In our clinic, um, we have a respiratory therapist who can do both erect and supine FVC.
- 29:36SPEAKER_03: And supine FEC is far more sensitive to pick up diaphragmatic dysfunction.
- 29:41SPEAKER_03: And if you have the opportunity, I would recommend that you do it routinely.
- 29:47SPEAKER_00: Sounds good.
- 29:48SPEAKER_00: We can uh Dr.
- 29:50SPEAKER_00: Muzapar, can you walk us through how the risk ratification framework determines who needs basic screening and who warrants a more intensive evaluation?
- 30:00SPEAKER_03: So, generally, um as a rule, juvenile onset myositis is not associated with cancer, so I would not routinely recommend cancer screening.
- 30:09SPEAKER_03: And similarly, the IBM cases generally don't have a risk for malignancy, and I would not recommend a routine screening in IBM patients.
- 30:20SPEAKER_03: Now, the other inflammatory myopathies, the risk factors are stratified based on the diagnosis and based on the serology.
- 30:29SPEAKER_03: So dermatomyocytes, especially the TIF1 gamma antibodies and the NXP2 antibodies, have the higher risk of malignancy, age above the age of 40, um, persistent height disease, history of smoking, or uh positive family history is important um on that.
- 30:49SPEAKER_03: So that's something that's important.
- 30:51SPEAKER_03: Uh, cutaneous necrosis or atypical skin lesions are suggestive of MDA5.
- 30:57SPEAKER_03: Um, and MDA5 has an association um with um uh this as well.
- 31:03SPEAKER_03: Intermediate risk factor would be um things like um polymycitis if it does exist, um IMNM um and um and so the other antibodies like HMGCR antibodies, MI2 antibodies, MDA5 antibodies, and SAE1 antibodies have an intermediate risk of malignancy.
- 31:25SPEAKER_03: Males uh gender is also an associated.
- 31:28SPEAKER_03: And then uh antisynthetase syndrome um generally overlap myopathies.
- 31:33SPEAKER_03: Um, if you have antibodies to JO1 or SRP, um they are not associated with malignancies, and I would not be too concerned about it.
- 31:43SPEAKER_03: Your your threshold for ordering these tests is going to be low.
- 31:47SPEAKER_03: Um, basic screening panel with blood work and ESR and CRP, but you really need to be looking at pan CT scan of the chest, abdomen, and pelvis, and mammography and a rectal exam.
- 32:04SPEAKER_03: And some such studies suggest that a pet imaging from the from the skull all the way down may be more sensitive.
- 32:13SPEAKER_03: Um we also have to particularly be concerned about nasopharyngeal carcinoma, especially in the Asian population.
- 32:22SPEAKER_00: Thank you, Dr.
- 32:22SPEAKER_00: Muzifer.
- 32:23SPEAKER_00: So when the patient comes in, it's important for you to not wait for patients to volunteer symptoms, but always ask for these questions: like are they having any difficulty swallowing, any problems with breathing, any respiratory muscle, your weakness, that your symptoms related to that, any decline?
- 32:40SPEAKER_00: Uh so these are some of the important things to look at.
- 32:45SPEAKER_00: Suppose Diane Diana tells you that she had stopped eating with her family because meals take too long.
- 32:51SPEAKER_00: Does that change your plan, Dr.
- 32:53SPEAKER_00: Nadaf, we want to pick that?
- 32:55SPEAKER_02: Definitely.
- 32:56SPEAKER_02: To me, that's an immediate referral to sleep and language pathology department to obtain a formal swallow evaluation and advise the patient how to safely swallow and whether there are certain types of food to avoid.
- 33:11SPEAKER_02: Swallowing, breathing, all of those can be a significant source of morbidity, and the patient may not necessarily directly link them to their muscle disease.
- 33:21SPEAKER_02: That's why we have to ask about them.
- 33:23SPEAKER_02: And there are also interventions that would follow.
- 33:26SPEAKER_02: Similarly, for sleep, they could they for neuromuscular respiratory weakness, those symptoms can be treated relatively similar to obstructive sleep apnea.
- 33:36SPEAKER_02: So it's important to acknowledge the symptoms and refer right away to the corresponding specialty.
- 33:46SPEAKER_00: That's good.
- 33:47SPEAKER_00: Thank you, Dr.
- 33:47SPEAKER_00: Nadal.
- 33:48SPEAKER_00: And so uh the operational message here is to name the owner and the return path.
- 33:54SPEAKER_00: So diffuse ownership, that is like, you know, we are working as a team, can be one reason screening obligations go unmet.
- 34:01SPEAKER_00: If you're like uh who wants the next step and what should be the first clinician doing before every referral is complete, you know, these are some of the questions that come up, and we need to make sure that uh we oh, you know, we understand that well.
- 34:16SPEAKER_00: And Dr.
- 34:17SPEAKER_00: Nadal, if you want to like uh take this and yeah, of course.
- 34:22SPEAKER_02: I think uh for myasitis patient in general, rather than the owner, or I would say the coordinating provider would be either the neurologist or the rheumatist.
- 34:32SPEAKER_02: As neurologists, we tend to take ownership of IBM, IMNM, or patients with predominant muscle manifestations.
- 34:42SPEAKER_02: Patients with a lot of with the systemic manifestation, they usually uh their care is most commonly coordinated by rheumatology.
- 34:51SPEAKER_02: And then you have all the team members that, depending on the patient needs that are listed there in the slides, that will chime in and provide recommendations, and while the care continue to be coordinated by the coordinating team or the primary provider.
- 35:08SPEAKER_03: I just wanted to emphasize the importance of multidisciplinary care and these myocytis patients.
- 35:13SPEAKER_03: So a combined myositis clinic with rheumatology is important because you learn a lot from them and they learn a lot from you, but they are unique, they're unique points of view that come in.
- 35:25SPEAKER_03: And we generally have a respiratory therapist and a physical therapist, and oftentimes a speech pathologist in that clinic, so you can take care of some of these issues.
- 35:33SPEAKER_00: I I agree with both of you that that is a very important uh point that we need a multidisciplinary care for these patients.
- 35:41SPEAKER_00: So, going back to our question of 68-year-old female, our case with the anti-JO1 positive is anti-synthetic syndrome, has progressive dyspnea and dry cough, unchanged muscle findings, FVC 68% predicted, and DLCO was 52% predicted.
- 35:57SPEAKER_00: Which next step should be prioritized.
- 36:18SPEAKER_00: All right, uh you can see the answer there.
- 36:22SPEAKER_00: Obtain high resolution CT and pulmonary evaluation now while maintaining.
- 36:28SPEAKER_00: Uh This is the answer there that you can see was by 65% uh pre and post was 70%.
- 36:39SPEAKER_00: So we do have uh some uh people that have changed there, but uh now you see the we can go on to the next one.
- 36:48SPEAKER_00: So our learning objective three is describe current and emerging steroid sparing and targeted treatment strategies in IAM, including the clinical rationale for FC receptor inhibition within a balanced therapeutic landscape.
- 37:03SPEAKER_00: So this is uh our next objective.
- 37:08SPEAKER_00: And let's look at the case here, Amber.
- 37:11SPEAKER_00: We have Amber, who is 58-year-old with anti-MI2 positive dermatomycitis.
- 37:16SPEAKER_00: Uh, she's been on prednisone for 14 months and currently on 15 milligrams daily.
- 37:21SPEAKER_00: She's on methotrexate for 11 months, 20 milligrams weekly, new hyperglycemia, about 8 and 8 kilogram weight gain.
- 37:30SPEAKER_00: And she's asked if whether anything would let her come off of a steroid.
- 37:34SPEAKER_00: So she would like to get off of that.
- 37:36SPEAKER_00: She has persistent proximal weakness and disabling fatigue.
- 37:39SPEAKER_00: She also has Gortran's papules, which are still active.
- 37:43SPEAKER_00: What factors should guide the decision to escalate our emerging therapies?
- 37:49SPEAKER_00: So here are the choice.
- 37:51SPEAKER_00: So we have this case who has this patient who has anti-MI2 positive, and we discussed his proximal weakness, disabling fatigue with steroid uh response, however, is on steroid for a long time, would like to get off of steroid, and uh also on methotrexate.
- 38:08SPEAKER_00: So, what which approach should guide the next treatment decision?
- 38:12SPEAKER_00: The patient also has some hypoglycemia from her uh medications and has weight gains.
- 38:35SPEAKER_00: Before we go on to treatment, we have to look at individual therapies.
- 38:40SPEAKER_00: We need to establish one principle in IAM treatments, that is, that they cannot be generalized across the IAM spectrum.
- 38:48SPEAKER_00: Dr.
- 38:49SPEAKER_00: Nedaf, can you walk us through how the treatment approach changes across dermatomyositis, antisynthetic syndrome, uh, immune neprotizing myopathy, and uh and why IBM needs to remain separate?
- 39:02SPEAKER_02: Definitely, there are separate entities that require separate treatment.
- 39:06SPEAKER_02: IBM is a progressive disease of aging where inflammation is just a part of the disease, and there are no there is no evidence to support the use of any currently available immunosuppressants in IBM.
- 39:20SPEAKER_02: So, therefore, in IBM we do not offer immunosuppression.
- 39:25SPEAKER_02: Now, from the other entities, there is an overlap between dermatomyazitis and anticentatase because they share similar patophysiology with inflammation in the muscle.
- 39:37SPEAKER_02: While IMNM is a distinct entity where on muscle biopsy you don't see inflammation, you just see the muscle fibers dying out, and we know there are the antibodies in the serum.
- 39:48SPEAKER_02: Um, so it's a different muscle biopsy finding reflecting different patophysiology.
- 39:54SPEAKER_02: So the traditional approach mostly apply in dermato in anticentatase, where you start with corticosteroid, and then you have your corticosteroid steroid agent available, and from there you could escalate depending on the response.
- 40:10SPEAKER_02: And obviously, we have now local treatments there approved for dermatomyzitis, such as IVIG and DREATO acetylene, jack inhibitor.
- 40:20SPEAKER_02: While in IMNM, the treatment is a little bit different because these patients do not tend to have a great response to steroids or oral immunosuppressants.
- 40:29SPEAKER_02: In my practice, the mainstay treatment in IMNM is actually IVIG.
- 40:35SPEAKER_02: Patients can have very good response to IVIG.
- 40:38SPEAKER_02: And in patients who do not respond well to IVIG, retoximab would be a second line.
- 40:44SPEAKER_02: Although in SRP positive IMNM, we could try retoximab a bit earlier on, obviously, depending on the case.
- 40:52SPEAKER_02: Then the others can be just add-on when we're not getting good enough response.
- 40:58SPEAKER_02: So our treatment options are a little bit more limited in IMNM.
- 41:04SPEAKER_00: Thank you, Dr.
- 41:04SPEAKER_00: Nadaf.
- 41:05SPEAKER_00: And going on to once the subtype and dominant disease manifestations are clear, the next question is how to use the conventional steroid sparing options without treating them as a fixed sequence.
- 41:17SPEAKER_00: So, Dr.
- 41:18SPEAKER_00: Nadaf, can you show how is how the disease domain and patient context guide which of these therapies may be reasonable?
- 41:27SPEAKER_02: Yes, of course.
- 41:28SPEAKER_02: So with the treatment, first we have to take in consideration obviously the particular disease that the patient has.
- 41:35SPEAKER_02: As I mentioned, for instance, before, just steroid or immunosuppressants may not be the go-to treatment in IMNF.
- 41:42SPEAKER_02: We also have to take in consideration the patient comorbidities.
- 41:46SPEAKER_02: And some patients, it can be very, for instance, very dangerous to use corticosteroids in them.
- 41:52SPEAKER_02: Now, the different immunosuppressants have different side effect profile to be also tailored to the particular patient.
- 42:00SPEAKER_02: For instance, we are more careful using metotrexate, or even better, avoided if there is interstitial lung disease in fear of lung toxicity.
- 42:11SPEAKER_02: So all of these are taken into consideration when selecting which steroid sparing therapies to choose, although these are considered off-label because there haven't been clinical trials for these agents.
- 42:24SPEAKER_02: They're considered off-label use.
- 42:29SPEAKER_00: Sounds good.
- 42:30SPEAKER_00: Thank you, Dr.
- 42:30SPEAKER_00: Nadaf.
- 42:31SPEAKER_00: Um, and we have um established the treatment here.
- 42:37SPEAKER_00: We have established the treatment cannot be approached the same way across all of them based on what you mentioned earlier.
- 42:43SPEAKER_00: And for Amber, we are specifically dealing with adult dermatomycitis, where there are now FDA-approved treatment options supported by distinct clinical trials.
- 42:52SPEAKER_00: Dr.
- 42:53SPEAKER_00: Musifer, can you walk us through what these what the data tells us about this?
- 42:59SPEAKER_03: Sure.
- 42:59SPEAKER_03: Um so in the last few years, we've been lucky to have two specific um treatment options approved for dermatomyocitis.
- 43:07SPEAKER_03: And this tape, this slide shows the two response, the two treatment options.
- 43:12SPEAKER_03: And I want to make sure that this is not a comparison slide.
- 43:15SPEAKER_03: Um intravenous immunoglobulins were approved about three or four years ago for treatment in dermatomyocytis based on a small study called ProDum, where the outcome measure that we used were the standard myositis measured, which is total improvement score, and the threshold was relatively modest, so a score of greater than 20 was considered as a positive outcome measure.
- 43:43SPEAKER_03: Some of the more recent trials have used a much more stringent uh total improvement score of 40 or higher, as you would see in the brepocetinep trial.
- 43:53SPEAKER_03: We were lucky to be part of both of the trials, but there was clearly a response.
- 43:57SPEAKER_03: The brepocetonep trial is Um was a larger trial of 240 subjects, and there were two different doses of prepocetinep.
- 44:06SPEAKER_03: And as I mentioned, the total improvement thresholds were higher with 40 percent 40 or more on that.
- 44:17SPEAKER_03: Obviously, to achieve the improvement in the total improvement scale score takes a little bit of a time.
- 44:26SPEAKER_03: And there is a placebo effect that is also prominent in all of these studies, as we have seen in some of the other neuromuscular trials.
- 44:34SPEAKER_03: And there are treatment emergent and treatment-related adverse events that occur as part of these studies.
- 44:41SPEAKER_03: None of these studies had serious infections in either of the studies, and there were no deaths in either of the trials.
- 44:53SPEAKER_00: Thank you, Dr.
- 44:54SPEAKER_00: Masapar.
- 44:55SPEAKER_00: So we had looked at the efficacy, and you did point out to some of the side effects, the safety, but uh based on this, like now let's look at the other side of the decision for our patient.
- 45:08SPEAKER_00: You know, we have the efficacy, but what are the safety concerns?
- 45:11SPEAKER_00: Other considerations should clinicians recognize when comp when comparing reasonable treatment options for a patient like Amber?
- 45:20SPEAKER_03: Sure.
- 45:20SPEAKER_03: So again, some of these are known side effects, and I will go over it.
- 45:24SPEAKER_03: So when you take into consideration intravenous immunoglobulins, there are infusion-related reactions that very commonly occur related to hypersensitivity, chills, fever, and headaches.
- 45:39SPEAKER_03: These are rate-dependent reactions that can be reduced if the rate is slowed down, and pre-medications with antihistamines and tyanol will help.
- 45:50SPEAKER_03: Infusion side reactions, especially if you're using uh subcutaneous IV immunoglobulins, can happen.
- 45:57SPEAKER_03: And hypertension is something that we see, and in extreme cases, you can get aseptic meningitis or treatment-related infusion reaction, which can be quite severe.
- 46:09SPEAKER_03: Breposetone causes risk for upper respiratory tract infections and urine tract infections.
- 46:15SPEAKER_03: There is also nausea, diarrhea, and for uh and fatigue that is common.
- 46:21SPEAKER_03: Um, and then there are risk of serious infections and hypersensitivity reactions with the class of drugs which uh reposetinop um belongs to as well.
- 46:32SPEAKER_03: Um, and again, with any of these drugs, risk of hypersensitory reaction um is expected in that.
- 46:40SPEAKER_03: Now, um there are black box warnings um for both of them, and Dr.
- 46:45SPEAKER_03: Ladaf uh will take us through that.
- 46:48SPEAKER_02: So basically with IVIG, the main thing to keep in mind is to increase the risk of clotting, um, and especially be more careful in patients with renal dysfunction or renal failure, that sometimes the dosage or certain formulation have to be used in those patients.
- 47:04SPEAKER_02: Brepositone has a uh books, sorry, have a warning for serious infection, mortality, malignancy, major adverse cardiovascular event, and thrombosis.
- 47:17SPEAKER_02: That's how they came with the FDA label.
- 47:23SPEAKER_00: Thank you.
- 47:23SPEAKER_00: And we can go back to the question here uh of a patient who has a 58-year-old with anti-MI2, positive dermatomycitis, persistent proximal weakness, disabling fatigue, and active gortrent papilles despite methotrexate.
- 47:36SPEAKER_00: So after 14 months of prednisone, she developed hypoglycemia.
- 47:40SPEAKER_00: And which approach should guide the next treatment decision for a patient?
- 47:45SPEAKER_00: So let's look at while while you're looking at the question answers, we can go over some of the questions online.
- 48:12SPEAKER_00: So could severe disease activity of the truncal muscles provoked uh restrictive pulmonary syndrome?
- 48:19SPEAKER_00: Does only PFT will provide the diagnosis?
- 48:28SPEAKER_02: So with axial muscle involvement, uh that can yes, weakening of the axial muscle because then the chest will lose its ability to expand.
- 48:37SPEAKER_02: That can show as a restrictive pattern on the PFTs.
- 48:41SPEAKER_02: And complementary tests we've mentioned overnight oximetry, and sometimes we even do a sleep study, a full sleep study to evaluate and also to intervene.
- 48:51SPEAKER_02: Usually, patient may need some BAP or other ventilatory support.
- 48:57SPEAKER_00: One other question I thought was interesting was in in IBM, uh, do you use the IBM-specific auto-antibody testing?
- 49:06SPEAKER_00: So that is a good question.
- 49:09SPEAKER_03: I I think you'll get a different answer from both me and uh Alive.
- 49:13SPEAKER_03: I I'm still a strong believer in it, um, and we are part of an NIH-funded natural history study that is looking at their role of this antibody, and those results should be coming out in the next um thing.
- 49:27SPEAKER_03: Um, it it does help, it's a the the challenges, and I'd love to hear Dr.
- 49:31SPEAKER_03: Nadav's view on it.
- 49:33SPEAKER_03: It does have high specificity.
- 49:34SPEAKER_03: It's the sensitivity is pretty low.
- 49:37SPEAKER_03: Um, but if you have muscle weakness and if you have antibodies, at least in our opinion, that does suggest strongly that you may be dealing with IBM.
- 49:46SPEAKER_02: Yeah, I actually widely use the antibody, so we're on the same side in that regard.
- 49:51SPEAKER_02: To me, it's most helpful when I'm not thinking of IBM and make me think of IBM.
- 49:57SPEAKER_02: So, in the right patient population, anyone with slowly progressive muscle disease, I tend to get the antibodies.
- 50:04SPEAKER_02: I don't diagnose IBM based on the antibody, but it helped me think about IBM in situations where otherwise I would not have considered it.
- 50:12SPEAKER_02: And you would be surprised how common IBM is.
- 50:16SPEAKER_02: Yes, agreed.
- 50:17SPEAKER_00: I agree with Dr.
- 50:18SPEAKER_00: Muzaffar too.
- 50:19SPEAKER_00: Like we do the same thing at uh KU.
- 50:22SPEAKER_00: So, right, let's go on uh to our.
- 50:25SPEAKER_00: We have the results here of that slide, and then uh this is a reference slide uh for audience to download.
- 50:33SPEAKER_00: Uh faculty may, you know, basically we can use that.
- 50:36SPEAKER_00: We have looked at the established treatment landscape.
- 50:39SPEAKER_00: Now let us widen the lens briefly to what is still being investigated in IAM.
- 50:45SPEAKER_00: Dr.
- 50:45SPEAKER_00: Muzaffar, can you orient us to this pipeline without uh turning into a list of individual agents?
- 50:52SPEAKER_03: Sure, I can I and I do not want to go into individual because the list is not complete and exhaustive in that sense, but the broad categories are there are B cell targeted strategies that are being employed, whether the whether we're talking about by specific antibodies that target different B cell approaches or targeted approach to CD19 or BCMA, which is plasma cell.
- 51:15SPEAKER_03: And the intent there is to reduce the antibody-producing cells.
- 51:19SPEAKER_03: You can also recycle the immunoglobulin or the antibodies that are disease specific, and that's where the FCRN antagonists come in, both with F-Cartigemot and the Bucalomap.
- 51:30SPEAKER_03: Um, and there it you are trying to metabolize or recycle the disease-causing anti uh the uh immunoglobulins.
- 51:39SPEAKER_03: And then there is the type 1 interferon pathway uh antagonism, which we've already talked about in terms of dermatomyocytis, but there are other trials also going on in dermatomyocitis, including the NFRillomab as well as the Sucrebat study, and then there are other studies that are emerging, especially T cell engagers that would may be coming online for some of these diseases, especially uh IMNM, um, and then there is an in emerging interest in Jack STAT inhibitors in IBM as well.
- 52:16SPEAKER_00: So, one of the investigational strategies is FC receptor inhibition.
- 52:21SPEAKER_00: Before we look at the trial results, Dr.
- 52:23SPEAKER_00: Ms.
- 52:24SPEAKER_00: Can you briefly explain why interfering with IgG recycling is biologically relevant in IAM?
- 52:31SPEAKER_03: Right.
- 52:31SPEAKER_03: So FCRN inhibition is a is a unique pathway.
- 52:35SPEAKER_03: Um, the immunoglobulins that the body produces are recycled in the endothelium through FCRN um uh receptors.
- 52:46SPEAKER_03: FCRN, anything that is bound to the FCRN receptor is not metabolized.
- 52:52SPEAKER_03: Anything that is free and not bound to the FCRN will get uh degraded and metabolized.
- 53:00SPEAKER_03: So this is a non-specific uh binding to the FCRN, so it could be good antibodies, it could be the disease-causing antibody, so it's a non-selective degradation of immunoglobulins.
- 53:13SPEAKER_03: But learning from diseases like mysthenia gravis, where we have learned that reduction of IgG can improve disease state, the same principle can apply to my antibody-associated myositis, that if you lower the antibody titers or the immunoglobulin titers, you can improve the disease state.
- 53:36SPEAKER_00: Now that we know the mechanism, uh Dr.
- 53:38SPEAKER_00: Nedaf, can you take uh tell us a little bit about the trial?
- 53:42SPEAKER_02: Yeah, of course.
- 53:43SPEAKER_02: So there's a trial for FCRN antagonist, the Alkivia trial in IIM, and these are the early part of the early phases of the trial, where 89 patients were treated with cartilagomod versus placebo, and there was a statistically significant improvement in the patient that received the drug compared to those that received the placebo when in the early phases that response was measured at 24 weeks.
- 54:14SPEAKER_02: And then for the phase three part of the trial, there when the drug was tested on a much larger population, we don't have those results yet.
- 54:23SPEAKER_02: We just heard the top-line results that these were positive and showed the improvement in patients that received the treatment versus the placebo.
- 54:32SPEAKER_02: But we look forward to see the detailed results of the phase phase three part of the trial.
- 54:39SPEAKER_00: Thank you, Dr.
- 54:40SPEAKER_00: Nidaf.
- 54:41SPEAKER_00: Um and uh going on to efficacy narrows the options, everything else decides between them.
- 54:47SPEAKER_00: Uh, as you can see here, uh, Dr.
- 54:50SPEAKER_00: There are options, narrows efficacy narrows options.
- 54:53SPEAKER_00: Um, Dr.
- 54:54SPEAKER_00: Nidaf, for a patient like Amber, what would move you towards or away from a reasonable option today?
- 55:02SPEAKER_02: Right.
- 55:03SPEAKER_02: I think it it really varies on a case-by-case basis.
- 55:07SPEAKER_02: In general, we don't switch as much between different oral immunosuppressants these days in diseases where there are some biologic available.
- 55:17SPEAKER_02: Um, as the patient failed prednisone and the traditional immunosuppressants, obviously, here we have the option of IVIG, and we have the option of a JAC inhibitor to be discussed based on the pros and cons of each of them to decide which one to go with.
- 55:37SPEAKER_02: One big advantage of IVIG in general, it is not an immunosuppressant, it's actually a drug that supplements the immune system.
- 55:46SPEAKER_02: Its main disadvantage is it's a longer infusion, and sometimes when given too quickly, can have some side effects, more like allergic reaction or some headaches.
- 55:57SPEAKER_02: But these would be the options to be discussed and decided based on the patient comorbidities and additional risk factors, whether she has risk uh prior history of clotting and so on and so forth.
- 56:12SPEAKER_00: Thank you, Dr.
- 56:13SPEAKER_00: Nadaf.
- 56:14SPEAKER_00: I mean, going on to the next uh slide here, uh these are the key takeaways from all of the discussions we had earlier.
- 56:21SPEAKER_00: Uh, and I'm not going to go through the details of this, but you can see IAM is a group of distinct disease, not one.
- 56:27SPEAKER_00: A negative myositis panel does not exclude IAM.
- 56:30SPEAKER_00: The organ that threatens the patient is often can be quiet.
- 56:33SPEAKER_00: So you need to uh ask the question steroid burden is treatment target and not inevitability.
- 56:39SPEAKER_00: So these are all uh the key takeaways, and then uh we would like uh to close the clinical portion by translating these lessons into measurable practice changes, the SMART goals.
- 56:50SPEAKER_00: Um Dr.
- 56:52SPEAKER_00: Dr.
- 56:52SPEAKER_00: Musafar and Dr.
- 56:54SPEAKER_00: Nadav, can you give us one practical practice poll before we end this that you most want learners to carry into clinic tomorrow?
- 57:03SPEAKER_03: Sure, I can start, and I would say that one important rule to think about is that there are false positives and false positives for everything, false negatives for everything.
- 57:13SPEAKER_03: So antibodies can have false positivity and false negativity.
- 57:17SPEAKER_03: Um use other ancillary tests to your advantage, and muscle pathology is an important tool.
- 57:25SPEAKER_02: I would just add that myozitis is not the only disease that progresses or the only myopathy that presents with rapidly progressive weakness.
- 57:34SPEAKER_02: So uh it could also be some other form of myopathy.
- 57:38SPEAKER_02: So keep an open mind about the diagnosis.
- 57:40SPEAKER_02: If there is any challenges that come up along the way, always revisit the diagnosis.
- 57:47SPEAKER_00: Thank you.
- 57:48SPEAKER_00: Thank you, Dr.
- 57:48SPEAKER_00: Nadaf.
- 57:49SPEAKER_00: And uh just before we wrap up uh this uh let's take a few questions here.
- 57:54SPEAKER_00: Is there any convincing uh data for methotrexate leads, uh methotrexate leads or exacerbates ILD?
- 58:06SPEAKER_00: And uh Dr.
- 58:07SPEAKER_00: Nadaf or Dr.
- 58:09SPEAKER_00: Mazufari, you want to take that?
- 58:10SPEAKER_00: Any convincing evidence?
- 58:11SPEAKER_03: I w I won't say they it exacerbates an interstitial lung disease, but methotrexate itself is associated with retroclural and retroperitoneal fibrosis, and that may aggravate the pulmonary condition from ILD, and that's one of the reasons we avoid methotrexate uh in somebody who has a known pulmonary disease.
- 58:33SPEAKER_00: Thank you.
- 58:34SPEAKER_00: Could you kindly give some information concerning diaphragmatic dysfunction and intercostal muscle dysfunction?
- 58:43SPEAKER_02: Go ahead, Ali.
- 58:46SPEAKER_02: Sorry, I was just asking, is it the diaphragm dysfunction?
- 58:49SPEAKER_00: Yeah, diaphragmatic dysfunction and intercostal muscle dysfunction.
- 58:53SPEAKER_00: I think we uh touched on some of it earlier in the in the butt but I I think this was one of the questions that came up.
- 59:00SPEAKER_02: So I would just mention that these are also muscles and they can be affected by meozitis, so that's why they present to the respiratory symptoms.
- 59:09SPEAKER_02: But when a patient has shortness of breath, it could still be related to weakening of the muscles rather than they have an interstitial lung disease.
- 59:18SPEAKER_00: Thank you, Dr.
- 59:19SPEAKER_00: Nadaf.
- 59:20SPEAKER_00: Um, I didn't know if we have more time, but uh there's this another question.
- 59:25SPEAKER_00: Could you kindly give more information about burnt out myositis that you mentioned earlier?
- 59:30SPEAKER_00: I think this is probably Dr.
- 59:34SPEAKER_00: Musifer.
- 59:34SPEAKER_00: I think you talked about it.
- 59:37SPEAKER_03: So there are patients who've had previous history of myositis and they have fixed muscle weakness, but that muscle weakness may not be because of active myositis.
- 59:49SPEAKER_03: And generally, in that situation, the CK would be low, the EMG would not show irritable myopathy.
- 59:57SPEAKER_03: And we this is one place where the MRI becomes really helpful because you want to look at the fat fraction in the muscle.
- 1:00:04SPEAKER_03: And generally, in burnt out myositis, you don't have a lot of stir signal, and you will have a lot of the muscles being replaced by fatty adipose tissue or fibrous tissue on that, and especially when selecting for clinical trials, that's is one of the criteria that we use that you have to have evidence for active muscle disease.
- 1:00:25SPEAKER_03: Persistent muscle weakness can happen from other causes.
- 1:00:30SPEAKER_03: Um, they may not always be related to muscle weakness.
- 1:00:33SPEAKER_00: Thank you, Dr.
- 1:00:34SPEAKER_00: Masafar.
- 1:00:35SPEAKER_00: Certified educational activities are available through the CME Outfitters at the website shown in the next slide.
- 1:00:42SPEAKER_00: Sorry.
- 1:00:43SPEAKER_00: These are the additional uh resources.
- 1:00:46SPEAKER_00: We thank you all for being on this, and thank you, Dr.
- 1:00:49SPEAKER_00: Masafar and Dr.
- 1:00:50SPEAKER_00: Nadaf for being uh leading this discussion here.
- 1:00:55SPEAKER_01: Thank you, Dr.
- 1:00:55SPEAKER_01: Pasnor.
- 1:00:57SPEAKER_01: Thank you.
- 1:00:58SPEAKER_01: Thank you all.